New combo therapy aims to tackle resistant lymphomas
NCT ID NCT07283822
First seen Jan 04, 2026 · Last updated Jun 22, 2026 · Updated 32 times
Summary
This phase II trial is testing whether adding the JAK inhibitor ruxolitinib to the immunotherapy drug pembrolizumab is safe and effective for people with relapsed or refractory Hodgkin and non-Hodgkin lymphomas. The study will enroll 53 participants with specific lymphoma subtypes, including peripheral T-cell lymphoma and cutaneous T-cell lymphoma. Participants will receive ruxolitinib for up to one year and pembrolizumab every three weeks, with researchers tracking response rates and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Columbia University Irving Medical Center
RECRUITINGNew York, New York, 10032, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ruxolitinib (a JAK inhibitor) and pembrolizumab (an immunotherapy drug)
What this could lead to
If successful, this combination could offer a new treatment option for people with hard-to-treat lymphomas that have not responded to standard therapies.
What could go wrong
This is a small, early-phase trial (phase II) with only 53 participants, so results may not apply to everyone. Side effects from the drug combination are possible and are being monitored.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.